Skip to main content

Advertisement

SpringerLink
Log in

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in patients with SSc-related ILD have shown that oral or intravenous cyclophosphamide is associated with modest but significant or near-significant improvements in lung function, dyspnea, and physical function. In addition, the Scleroderma Lung Study and an observational study showed that baseline forced vital capacity less than 70% and moderate fibrosis on thoracic high-resolution CT are predictors of response to cyclophosphamide therapy and/or survival, whereas active alveolitis on bronchoalveolar lavage is not. Newer therapies for SSc patients with ILD include mycophenolate mofetil, tyrosine kinase inhibitors (imatinib, dasatinib), and anti-interleukin-13 monoclonal antibody. Several uncontrolled trials have reported favorable results of mycophenolate mofetil in SSc-related ILD. A randomized double-blind controlled trial by the Scleroderma Lung Study Research Group is currently comparing the efficacy and safety of mycophenolate mofetil versus oral cyclophosphamide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Steen VD, Medsger TA Jr: Changes in causes of death in systemic sclerosis. Ann Rheum Dis 2007, 66:940–944.

    Article  PubMed  Google Scholar 

  2. Beon M, Harley RA, Wessels A, et al.: Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 2004, 22:733–742.

    PubMed  CAS  Google Scholar 

  3. Scala E, Pallotta S, Frezzolini A, et al.: Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540–546.

    Article  PubMed  CAS  Google Scholar 

  4. Bogatkevich GS, Gustilo E, Oates JC, et al.: Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005, 288:L190–L201.

    Article  PubMed  CAS  Google Scholar 

  5. Shi-Wen X, Chen Y, Denton CP, et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15:2707–2719.

    Article  PubMed  Google Scholar 

  6. Abraham DJ, Vancheeswaran R, Dashwood MR, et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151:831–841.

    PubMed  CAS  Google Scholar 

  7. Leask A: Targeting the TGF-beta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008, 20:1409–1414.

    Article  PubMed  CAS  Google Scholar 

  8. Krieg T, Abraham D, Lafyatis R: Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007, 9(Suppl 2):S4.

    Article  PubMed  Google Scholar 

  9. Bouros D, Wells AU, Nicholson AG, et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581–1586.

    Article  PubMed  Google Scholar 

  10. Steen VD, Conte C, Owens GR, Medsger TA Jr.: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  11. Strange C, Bolster MB, Roth MD, et al.: Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008, 177:91–98.

    Article  PubMed  CAS  Google Scholar 

  12. Latsi PI, du Bois RM, Nicholson AG, et al.: Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531–537.

    Article  PubMed  Google Scholar 

  13. Goldin JG, Lynch DA, Strollo DC, et al.: High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008, 134:358–367.

    Article  PubMed  Google Scholar 

  14. Goh NS, Desai SR, Veeraraghavan S, et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248–1254.

    Article  PubMed  Google Scholar 

  15. Steen VD, Medsger TA Jr, Rodnan GP: D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982, 97:652–659.

    PubMed  CAS  Google Scholar 

  16. Clements PJ, Furst DE, Wong WK, et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999, 42:1194–1203.

    Article  PubMed  CAS  Google Scholar 

  17. Furst DE, Clements PJ, Hillis S, et al.: Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989, 32:584–593.

    Article  PubMed  CAS  Google Scholar 

  18. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646–664.

    Google Scholar 

  19. Lynch JP III, Saggar R, Weigt SS, et al.: Usual interstitial pneumonia. Semin Respir Crit Care Med 2006, 27:634–651.

    Article  PubMed  Google Scholar 

  20. Silver RM, Warrick JH, Kinsella MB, et al.: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993, 20:838–844.

    PubMed  CAS  Google Scholar 

  21. Steen VD, Lanz JK Jr, Conte C, et al.: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994, 37:1290–1296.

    Article  PubMed  CAS  Google Scholar 

  22. White B, Moore WC, Wigley FM, et al.: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947–954.

    PubMed  CAS  Google Scholar 

  23. Akesson A, Scheja A, Lundin A, Wollheim FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994, 37:729–735.

    Article  PubMed  CAS  Google Scholar 

  24. Behr J, Vogelmeier C, Beinert T, et al.: Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996, 154:400–406.

    PubMed  CAS  Google Scholar 

  25. Schnabel A, Reuter M, Gross WL: Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998, 41:1215–1220.

    Article  PubMed  CAS  Google Scholar 

  26. Varai G, Earle L, Jimenez SA, et al.: A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998, 25:1325–1329.

    PubMed  CAS  Google Scholar 

  27. Pakas I, Ioannidis JP, Malagari K, et al.: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002, 29:298–304.

    PubMed  CAS  Google Scholar 

  28. Giacomelli R, Valentini G, Salsano F, et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002, 29:731–736.

    PubMed  CAS  Google Scholar 

  29. Griffiths B, Miles S, Moss H, et al.: Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002, 29:2371–2378.

    PubMed  CAS  Google Scholar 

  30. Tashkin DP, Elashoff R, Clements PJ, et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655–2666.

    Article  PubMed  CAS  Google Scholar 

  31. Khanna D, Yan X, Tashkin DP, et al.: Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. Arthritis Rheum 2007, 56:1676–1684.

    Article  PubMed  CAS  Google Scholar 

  32. Goldin JG, Lynch DA, Strollo DC, et al.: Follow-up HRCT after treatment of scleroderma-interstitial lung disease with cyclophosphamide demonstrates evidence for treatment effect [abstract]. Am J Respir Crit Care Med 2008, 177:A882.

    Google Scholar 

  33. Martinez FJ, McCune WJ: Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006, 354:2707–2709.

    Article  PubMed  CAS  Google Scholar 

  34. Tashkin DP, Elashoff R, Clements PJ, et al.: Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176:1026–1034.

    Article  PubMed  CAS  Google Scholar 

  35. Hoyles RK, Ellis RW, Wellsbury J, et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962–3970.

    Article  PubMed  CAS  Google Scholar 

  36. Takebe N, Cheng X, Fandy TE, et al.: IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006, 5:457–466.

    Article  PubMed  CAS  Google Scholar 

  37. Colic M, Stojic-Vukanic Z, Pavlovic B, et al.: Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003, 134:63–69.

    Article  PubMed  CAS  Google Scholar 

  38. Andrikos E, Yavuz A, Bordoni V, et al.: Effect of cyclosporine, mycophenolate mofetil, and their combination with steroids on apoptosis in a human cultured monocytic U937 cell line. Transplant Proc 2005, 37:3226–3229.

    Article  PubMed  CAS  Google Scholar 

  39. Kaminska D, Tyran B, Mazanowska O, et al.: Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RTPCR analysis. Transplant Proc 2005, 37:770–772.

    Article  PubMed  CAS  Google Scholar 

  40. Liossis SN, Bounas A, Andonopoulos AP: Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006, 45:1005–1008.

    Article  CAS  Google Scholar 

  41. Nihtyanova SI, Brough GM, Black CM, Denton CP: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology (Oxford) 2007, 46:442–445.

    Article  CAS  Google Scholar 

  42. Zamora AC, Wolters PJ, Collard HR, et al.: Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008, 102:150–155.

    Article  PubMed  Google Scholar 

  43. Gerbino AJ, Goss CH, Molitor JA: Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008, 133:455–460.

    Article  PubMed  CAS  Google Scholar 

  44. Swigris JJ, Olson AL, Fischer A, et al.: Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130:30–36.

    Article  PubMed  CAS  Google Scholar 

  45. Reichenberger F, Schauer J, Kellner K, et al.: Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001, 179:163–174.

    Article  PubMed  CAS  Google Scholar 

  46. King TE Jr, Behr J, Brown KK, et al.: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75–81.

    Article  PubMed  CAS  Google Scholar 

  47. Varga J: Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002, 46:1703–1713.

    Article  PubMed  CAS  Google Scholar 

  48. Denton CP, Merkel PA, Furst DE, et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2006, 56:323–333.

    Article  Google Scholar 

  49. Distler JH, Distler O: Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) 2009, 48:2–4.

    Article  CAS  Google Scholar 

  50. Daniels CE, Wilkes MC, Edens M, et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308–1316.

    PubMed  CAS  Google Scholar 

  51. Akhmetshina A, Dees C, Pileckyte M, et al.: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008, 22:2214–2222.

    Article  PubMed  CAS  Google Scholar 

  52. Richter A, Puddicombe SM, Lordan JL, et al.: The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001, 25:385–391.

    PubMed  CAS  Google Scholar 

  53. Hancock A, Armstrong L, Gama R, Millar A: Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998, 18:60–65.

    PubMed  CAS  Google Scholar 

  54. Simms RW, Korn JH: Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 2002, 14:717–722.

    Article  PubMed  CAS  Google Scholar 

  55. Zhu Z, Homer RJ, Wang Z, et al.: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779–788.

    Article  PubMed  CAS  Google Scholar 

  56. Belperio JA, Dy M, Burdick MD, et al.: Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002, 27:419–427.

    PubMed  CAS  Google Scholar 

  57. Dheda K, Lalloo UG, Cassim B, Mody GM: Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004, 23:306–309.

    PubMed  CAS  Google Scholar 

  58. Nadashkevich O, Davis P, Fritzler M, Kovalenko W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006, 25:205–212.

    Article  PubMed  CAS  Google Scholar 

  59. McSweeney PA, Nash RA, Sullivan KM, et al.: High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002, 100:1602–1610.

    PubMed  CAS  Google Scholar 

  60. Nash RA, McSweeney PA, Crofford LJ, et al.: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388–1396.

    Article  PubMed  CAS  Google Scholar 

  61. van Laar J, Farge D, Tyndall A: ASTIS trial news: latest news. Available at http://www.astistrial.com/ASTISnews.HTM. Accessed December 15, 2008.

  62. Walker UA, Tyndall A, Czirjak L, et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754–763.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA, 90095, USA

    Donald P. Tashkin

Authors
  1. Karen Au
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dinesh Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip J. Clements
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel E. Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donald P. Tashkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald P. Tashkin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Au, K., Khanna, D., Clements, P.J. et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. Curr Rheumatol Rep 11, 111–119 (2009). https://doi.org/10.1007/s11926-009-0016-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0016-2

Keywords

Search

Navigation